Agoracom Blog Home

Archive for the ‘Lexaria Corp.’ Category

« Older Entries
Newer Entries »

Lexaria Letter From the President

Posted by AGORACOM-JC at 8:09 AM on Tuesday, February 24th, 2015

Kelowna, British Columbia–(Newsfile Corp. – February 24, 2015) – Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) is pleased to provide a Letter From the President for all its stakeholders.

Lexaria has posted at its website www.lexariaenergy.com a letter from the president, outlining recent corporate activity and current and future business plans. The complete Letter from the President is also being filed with regulators in the USA and Canada, and sent directly to shareholders. A summary and excerpt from the letter follows.

I am pleased to offer this update on Lexaria Corp to all stakeholders, following many changes in the Company during the past year.

It is a particularly exciting time in the Company’s history. 2014 delivered the sharpest and most severe decline in oil prices in over 5 years, and one of the biggest declines of all time. In 2012 we quietly initiated efforts to maximize value from our Belmont Lake oil field through any means possible, including a complete asset sale.

The oil field was sold late in 2014. At a peak, we owed over $1.7 million to various creditors, much of this to management and directors who had provided significant loans to enable our operations. We are proud to have paid all these loans down to a zero balance and that every creditor was paid in full.

At our annual general meeting in 2014, you responded overwhelmingly in favor of our entry into the medical marijuana sector, and we have responded with vigor. We now have a joint venture that has applied to Health Canada, the governing body of the medical marijuana industry in Canada, for a license to produce 10,000 kg (approx 22,000 pounds) of medical marijuana per year. Lexaria owns 49% of that joint venture.

Meanwhile, we don’t want to either bet the entire company on a single license application; or ignore the much larger market for already-legal agricultural hemp products. It’s important to clearly understand our foray into the United States market: In the USA we do not sell cannabis and are not involved in the marijuana trade in any way, even in those states where it is legal to do so under state law.

We are proud to help people in their quest for health and wellness, and we have come to believe that CBD may play an integral role in general good health. As a publicly traded company we believe this is not only the more prudent path for our company to take on behalf of its investors, but also the more profitable one.

Having unveiled our www.vipova.com website and upon selling our first cup of tea, we became a national company able to sell our CBD infused tea – using patent-pending technology – anywhere in the United States.

In order to attempt to generate sales revenue, and with them, our expectations of eventual profits, we purchased 51% of PoViva Tea LLC and launched the ViPovaTM brand of Cannabidiol (CBD) infused teas. Of all the steps we’ve taken in guiding Lexaria forward over recent years, we are perhaps most excited about our entry into the CBD business. Lexaria is playing a leading role in this brand new industry by delivering CBD through our unique and distinctive lipid-infused process making it one of the most exciting emerging companies in the business today.

2015 will be a very busy year for us – we have a number of goals and initiatives.

Primary among these is to establish ViPovaTM as a widely recognized and trusted brand for delivering CBD using our patent pending process that we believe is more effective and comforting. As brand recognition grows we intend to broaden the brand with other products, such as flavored teas and coffee. ViPovaTM sales and product introductions will constantly be a focus during 2015.

We will also launch our second brand of products under the Lexaria Energy brand, keeping a smile on our corporate face as we use our original name for new purposes. Lexaria Energy will be launched in the first 6 months of 2015 as a line of nutritional supplements for active people, once again always using our patent pending technology to infuse CBD inside for comfort and effectiveness.

We expect our first product to be a CBD/Protein bar of exceptional quality and taste. We are hoping to make the Lexaria Energy Bar the only bar in the world that is low on the glycemic index; gluten-free; and incorporates CBD with our patent-pending technology. It is currently under development.

2014/2015 is a period of change for your company. We know we made the right move to back away from the oil and gas business, and the economics in that business have deteriorated even more rapidly than we feared they might. We have paid all our bills and debts so that the Company is not burdened or placed at risk. We’ve entered the medical marijuana business through a license application in Canada. And we are launching two new brands in the USA aimed at the exciting brand new fields of cannabidiol delivery.

Though there has been a lot of change, one thing in particular remains constant: our thanks to you our shareholders for your loyalty and steadfastness over the years. It is hard being a mouse among elephants but we’ve tried our best to work hard for you all the while we avoid being stepped on. Our commitment to you remains unchanged and we will work honestly and tirelessly on your behalf.

Sincerely,

Chris Bunka

President and CEO, Lexaria Corp .

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. www.lexarienergy.com

About ViPovaTM

ViPovaTM uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPovaTM has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , , , ,
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Letter From the President

ViPova (TM) by Lexaria Launches National Sales Initiative

Posted by AGORACOM-JC at 8:06 AM on Monday, February 23rd, 2015

Kelowna, British Columbia–(February 23, 2015) – Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) announces that ViPovaTM by Lexaria has launched a national US initiative designed to assist Americans to simultaneously achieve two important objectives:

1) To try new ViPovaTM CBD-infused tea, hold a TEA PARTY in your home or office. The President of ViPova or another Lexaria/ViPova member will personally visit with you; share ViPovaTM Tea amongst the group; provide information; answer questions; and, invite participants to become Channel Partner Distributors.Contact ViPovaTM through our website or by email at [email protected], to make your request to host a ViPovaTM TEA PARTY. In order to qualify to host your TEA PARTY, certain criteria, not limited to the following, must be met: a minimum of 12 people over the age of 21 must attend the TEA PARTY. We will consider all TEA PARTY requests and follow up with you regarding possible dates and schedules, as we roam across the country.
2) Not only will TEA PARTY participants have a chance to enjoy great-tasting ViPovaTM tea with no obligation, they will also be able to apply on the spot at these unique events to become authorized CHANNEL PARTNER Distributors of ViPovaTM products. In addition to receiving extensive, industry leading product training, distributors will have the potential to earn an exciting supplementary income selling ViPovaTM products. Persons wishing to become ViPovaTM distributors can also apply by downloading an application form available at www.vipova.com A limited number of CHANNEL PARTNER distributorships will be available in each state in the country. Interested distributors or TEA PARTY hosts can also email us at [email protected] with your contact information and we will respond asap.

ViPovaTM by Lexaria is the country’s first CBD/Lipid-infused tea, and we are excited to launch this initiative to establish the nation’s best trained direct sales force for this highly anticipated brand launching.

Consumers across all 50 states can now buy America’s FIRST product that uses patent-pending technology to infuse CBDs within lipids for the most comforting and effective experience possible. As 2015 unfolds, ViPovaTM expects to offer additional products to its lineup.

As well, the Lexaria EnergyTM brand will also be launched in the first half of 2015 and ViPovaTM CHANNEL PARTNER Distributors will automatically be eligible to also sell the full line of Lexaria EnergyTM brand products as they are unveiled. Broadening our product offerings, combined with early geographic sales advantages, will make this opportunity to quickly acquire Distributor rights particularly rewarding.

The www.vipova.com website and our toll-free phone lines are taking tea orders. Customers can call 1-888-976-8482 from 9AM to 7PM EST Mon-Fri and we accept most major credit cards.

For a limited time only, our two introductory offers remain valid: on your first order, please enjoy free shipping and a coupon good for 30% off your subsequent order, regardless of order size.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. www.lexarienergy.com

About ViPovaTM

ViPovaTM uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPovaTM has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , , , ,
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on ViPova (TM) by Lexaria Launches National Sales Initiative

Clinical trials high on list for medical marijuana community

Posted by AGORACOM-JC at 2:42 PM on Tuesday, February 17th, 2015

The medical marijuana movement is asking the scientific community to make examining the therapeutic potential of cannabis in much more depth a priority, cannabis experts from North America and the UK declared on 14 February at the American Association for the Advancement of Science (AAAS) annual meeting in California. But the drug’s controlled status is continuing to slow efforts to investigate the myriad compounds in the plant.

The panellists said the evidence is clear that cannabinoids can treat different types of pain effectively. In addition, they cited some evidence that cannabinoids help with neurological conditions like epilepsy. There is also very early clinical trial data suggesting that the molecule cannabidiol (CBD) has an antipsychotic effect and some evidence that it could help with anxiety disorders.

Although cannabis use is associated with things like short-term memory loss and learning problems, the experts presented data showing that once use is stopped those effects disappear within a few days. They also said there is no proof of any long-term neurocognitive effects of chronic marijuana use on the adult brain, although there is some cause for concern about heavy use by adolescents.

The question of whether the compounds have untoward effects remains unclear due to insufficient research. The field is stalled because large clinical trials require the deep pockets of the pharmaceutical sector, but a major barrier is the lack of intellectual property around some of these compounds. ‘They are old drugs, they are hard to lock in patents, and that makes it difficult for someone to invest significantly into these kinds of research studies that might not have the long-term payback,’ explained Mark Ware, who runs the pain research unit at McGill University, Canada.

However, possession of cannabis is still illegal in most US states making it a difficult drug to work with in the clinic. Igor Grant, a neuropsychiatrist who directs the cannabis research centre at the University of California, San Diego, US, has conducted seven clinical trials that involved smoked or inhaled cannabis and all required that he obtain regulatory approvals from three separate agencies before he could even acquire the cannabis for the studies.

Research marijuana for the US is grown by University of Mississippi under government licence. Once investigators clear all of the approvals, they can request the study drug from the NIH in the form of cigarettes containing different concentrations of tetrahydrocannabinol or THC – the main psychoactive constituent of cannabis.

Cannabis in Canada

Cannabis research is far easier to pursue in Canada where there is a regulated government programme. The country controls cannabis differently to other drugs, arguing that it fits neither under natural health product regulations that govern the use of herbal medicines, nor under the pharmaceutical drug regulations.

Some of the Canadian companies that grow cannabis under licence are now funding clinical trials to try and develop a drug, according to Ware. ‘The money is out there, but the trick is to get these kinds of pilot studies – proof-of-concept studies – done that encourage people to do larger-scale trials,’ he said.

The experts agreed that more information is needed about therapeutic use of cannabis. To help fill this gap, the provincial ethics committee in Quebec recently directed that all patients cleared to use cannabis for medical reasons must agree to be part on an ongoing study. Ware has been tapped to help set up a Quebec-wide registry that will allow these patients to be tracked anonymously for adverse events, as well as for things like pain, spasticity, appetite level and mood. The registry is expected to go live by the end of March.

In the US, there has been much media and public interest in a strain of medical marijuana first developed to treat a child suffering from repeated seizures, dubbed Charlotte’s Web, which is high in CBD but does not contain any psychoactive compounds. But Ware is troubled by the phenomenon of parents and patients seeking out CBD therapeutics. ‘We don’t know where the cannabidiol is coming from; there is a tremendous kind of mythology about the stuff coming from eastern Europe or China,’ he said. Hemp farmers in Canada are being approached to produce CBD and are charging huge amounts of money, he added.

The development of such medicinal products is complicated by the fact that cannabis contains over 100 different ingredients that may be bioactive. This flies in the face of the model followed by regulatory agencies like the US Food and Drug Administration that are set up to deal with single molecules rather than complex mixtures.

Source: http://www.rsc.org/chemistryworld/2015/02/clinical-trials-high-list-medical-marijuana-community

Tags: , , , ,
Posted in Enertopia, Enertopia Corp., GrowPros Cannabis Inc., Lexaria Corp., Medical Marijuana Stocks, Next Gen, Supreme Pharmaceuticals Inc | Comments Off on Clinical trials high on list for medical marijuana community

Lexaria Hires National Sales Strategist and Sponsors First Sales Event

Posted by AGORACOM-JC at 8:06 AM on Friday, February 13th, 2015

KELOWNA, BC / February 13, 2015 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company”) announces that ViPova(TM) by Lexaria is sponsoring its first major sales event; and also announces the hiring of a National Sales Strategist.

Lexaria has hired a National Sales and Compliance Strategist to execute the Company’s sales initiatives across the United States. He has a successful history of building sales teams and developing sales channels from within the fast-growing hemp industry, and is intimately familiar with industry regulations and sales strategies that deliver results. Lexaria has tasked him with developing and fine tuning regulatory-specific sales initiatives for the ViPova(TM) CBD-infused tea, as well as for other ViPova(TM) products currently in development or under consideration.

Strategies for opening sales channels for Lexaria Energy(TM) branded products, beginning with a CBD-infused protein energy bar are also being developed. Lexaria will provide additional information about that product launch when available, expected in Q2, 2015. Lexaria is in the early stages of rolling out methods for increasing awareness for ViPova(TM) tea as well as other products being considered.

In coordination with this, Lexaria is pleased to be the official sponsor of the Heritage Classic Dancesport Championships competition, to be held March 3-7 in Asheville, NC. This major dance event, sanctioned by the National Dance Council of America, is expected to be attended by as many as 10,000 people, many of whom are professional or serious amateur dancers. The Heritage Classic has won the dance “Competition of the Year” award three times and will be awarding more than $110,000 in cash and scholarships.

Lexaria has found an exciting niche among competitive dancers who have already begun purchasing and drinking ViPova(TM) tea. “Professional dancers seem quite interested in our tea,” says Chris Bunka, CEO of Lexaria Corp. “We are very pleased to be able to support this prestigious event and have the chance of answering questions and raising awareness of ViPova(TM) among this year’s participants in the Heritage Classic.”

Lexaria is identifying additional niche markets where it feels its marketing can be tightly focused for maximum effect. Announcements on other specific events and opportunities will be made in due course, as the year unfolds.

The new www.vipova.com website is accepting major credit cards, and taking orders. We have ViPova(TM)Tea in-stock and ready to ship. Customers can also call 1-888-976-8482 from 9AM to 7PM EST Mon-Fri to place their tea orders.

For a limited time only, our two introductory offers remain valid: on your first order, please enjoy free shipping and a coupon good for 30% off your subsequent order, regardless of order size.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. www.lexarienergy.com

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Tags: , , , ,
Posted in Lexaria Corp., McLaren Resources | Comments Off on Lexaria Hires National Sales Strategist and Sponsors First Sales Event

Lexaria Updates Operations

Posted by AGORACOM-JC at 9:45 AM on Wednesday, February 4th, 2015

KELOWNA, BC / February 4, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) provides the following three operational updates.

CREDIT CARDS

Lexaria is pleased to announce it is now accepting Mastercard and Visa credit card payments at its www.vipova.com e-commerce site for sales of its patent-pending CBD-infused black tea across America. Previously, customers could only transact with the ViPova website with checks and money orders, and while these payment options remain for those who prefer them, Vipova’s ability to accept major credit cards will shorten delivery times and provide the ease of ordering that customers expect.

Given the increase in web traffic Vipova.com has experienced, Lexaria believes the ability to use credit cards should lead to an increase in sales volumes. Customers across the US can also call 1-888-976-8482 from 9AM to 7PM EST Mon-Fri to place their orders.

FOCUS GROUPS

Lexaria has begun holding focus group sessions to introduce and evaluate its CBD-infused black tea. Our first focus group was held January 29 when 14 people were introduced to ViPova Tea. The session provided a chance for potential consumers to learn about the tea and the properties of cannabidiol infusion, and proved immensely valuable to the Company to learn about consumer preferences, needs, likes and dislikes.

Lexaria is very pleased at the enthusiastic response and comments received. Participants had the opportunity to meet senior representatives of ViPova, and provide detailed commentary that the Company will use to fine-tune its products and marketing as 2015 unfolds.

The next focus group will be held during the next several days and the Company expects to continue to hold similar focus group meetings in the weeks and months to come.

STRATEGIC ADVISOR

Lexaria has engaged Sequoia Partners Inc for strategic fiscal advisement and for the development of various strategies to assist the Company to realize its project objectives. Lexaria will be working closely with the Managing Partners of Sequoia to pursue its interests. The Managing Partners have extensive and long lasting relationships in the finance, health care and pharmaceutical industries that are expected to be beneficial to the Company.

Sequoia has been granted 250,000 stock options and will receive a monthly fee of CDN$5,000 for the next six months.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. www.lexariaenergy.com.

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate”, “if”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “could”, “should”, “will”, and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Tags: , , , , , , ,
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Updates Operations

Lexaria Maintains OTCQB Marketplace Status

Posted by AGORACOM-JC at 1:28 PM on Monday, February 2nd, 2015

KELOWNA, BC / February 2, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) announces the Company has submitted all the mandatory documents and has successfully met all of the requirements for continued listing and trading on the OTCQB Marketplace. Partly as a result of this, Realtime Level II Quote Display Service is now available to investors free at www.otcmarkets.com/stock/LXRP/quote.

Lexaria is a US Company that trades in the USA on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies. Companies listed at OTCQB are current in their reporting and undergo an annual verification and management certification process. Lexaria has continuously filed its quarterly and annual reports, and more, at the SEC “EDGAR” site since 2006.

Since 2009, Lexaria also has traded on the Canadian Securities Exchange in Canada, the fastest growing stock exchange in North America. Lexaria is eligible for registered retirement accounts for Canadian investors, is compliant with all CSE regulatory policies, and is Fully Reporting under Canadian securities laws.

Lexaria is pleased to continue its open and transparent communications and accessibility with its investors across North America and expects this tradition to continue in 2015 and beyond.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. www.lexariaenergy.com/.

About ViPova(TM)

ViPova(TM)uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate”, “if”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “could”, “should”, “will”, and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , , , ,
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Maintains OTCQB Marketplace Status

Legal Marijuana is Now the Fastest Growing Industry in America

Posted by AGORACOM-JC at 1:16 PM on Tuesday, January 27th, 2015

Legal Marijuana is Now the Fastest Growing Industry in America

Indulging in the green is no longer just a cocktail conversation – it’s big business.

According to researchers from cannabis industry investment and research firm The ArcView Group, the legal marijuana market in the United States ballooned to $2.7 billion last year, growing 74 per cent from 2013 to become the fastest-growing industry in the nation.

That’s a lot of weed sales – and a major boost to the economy business leaders are all of a sudden taking very seriously.

Just ask former US Senator Mike Gravel.

What’s especially impressive is only four states have legalized adult cannabis use and sales, with another eight expected to jump on board by the end of next year.

If legalization is eventually enacted across all 50 states, the legal marijuana industry is projected to become larger than the organic food industry.

And while the U.S. is blazing the trail, we can probably expect a budding cannabis business to boost Canada’s GDP in the near future – Trudeau 2015, anyone? After all, everything that happens in the U.S. eventually becomes big North of the Border.

Who would have guessed that the most effective recovery from the next recession could be to smoke ourselves out?

Certainly not what we learned in economics class.

#NOTABLE

Want more updates on the most Notable things happening so you know before your colleagues do? Get our exclusive newsletter here and follow us on Twitter for all the latest.

Source: http://notable.ca/nationwide/yp-life/Legal-Marijuana-is-Now-the-Fastest-Growing-Industry-in-America/

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , ,
Posted in Enertopia Corp., Lexaria Corp., Medical Marijuana Stocks, Next Gen | Comments Off on Legal Marijuana is Now the Fastest Growing Industry in America

Lexaria Announces ViPovaTM Website for CBD Research and Direct Tea Sales

Posted by AGORACOM-JC at 9:46 AM on Thursday, January 15th, 2015

KELOWNA, BC / January 15, 2015 / Lexaria, Corp. (LXRP) (CSE:LXX) (the “Company”) announces that ViPova(TM) by Lexaria has launched a new website at www.vipova.com. The new site is live and contains research on tea, cannabinoids (CBD) and cannabidiol.

Consumers across all 50 states can now buy America’s FIRST product that uses patent-pending technology to infuse CBDs within lipids for the most comforting and effective experience possible.

The new www.vipova.com website will take your orders now and we have ViPova(TM) Tea in-stock and ready to ship today. Customers can also call 1-888-976-8482 from 9AM to 7PM EST Mon-Fri to place their orders. We are not yet ready to accept credit cards as payment, but expect to be able to add that feature soon.

For a limited time only, we have two introductory offers to thank our first customers:

Our earliest customers will receive a coupon with their first order of ViPova(TM) Tea; the coupon is good for 30% off your second order, and your second order can be any size you like. Only one coupon will be available to each customer. Also for a limited time, get free shipping anywhere in the USA for your tea order – we pay the cost of delivering the tea to you. www.vipova.com is more than just the first online location to sell ViPova(TM) Tea. It is also a leading location for research on cannabinoids, allowing visitors to learn for themselves of the many studies already conducted on CBD’s. Research will be regularly updated and broadened and everyone is encouraged to visit to learn of the wondrous properties of cannabidiol.

We also are launching an online community and blog at the website; users will have the opportunity to share their personal experiences with the therapeutic and wellness effects of cannabinoids and customer experiences with ViPova Tea. Over time we hope that users will share knowledge, recipes and other information.

As well, ViPova(TM) co-founder and consultant to Lexaria Dr. Michelle Reillo, will write a regular blog feature available only at www.vipova.com, sharing her extensive knowledge on the endocannabinoid system and how her research has suggesting that good overall health is perhaps not possible when the endocannabinoid system is compromised or weakened.

It is our hope that over time, www.vipova.com will become the leading portal for knowledge, research, personal experiences and, of course, a venue to purchase products from Vipova(TM) all related to cannabinoids.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. www.lexariaenergy.com

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate”, “if”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “could”, “should”, “will”, and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , , , ,
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Announces ViPovaTM Website for CBD Research and Direct Tea Sales

Lexaria Commissions Cannabinoid Education Series

Posted by AGORACOM-JC at 8:19 AM on Thursday, January 8th, 2015

Kelowna, British Columbia–(January 8, 2015) – Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) has engaged Michelle Reillo, PhD, to write a series of manuals providing guidance to both consumers of CBD and practitioners who advise patients in their use of CBD. This wide ranging series will offer guidance and instruction as to how to maximize performance, health, and wellness through the proper and regimented consumption of Cannabidiol.

Lexaria recognizes there is an enormous information vacuum with respect to cannabidiol (CBD), its usage, and the health benefits it provides. For those who wish to immediately learn more, we refer you to the beta version of our www.vipova.com website where you can find the US Government’s patent on cannabidiol, Patent # 6630507, which provides a broad overview of the health benefits associated with CBD.

The Lexaria education series will address how the human endocannabinoid system functions as the body’s circuit board, essentially connecting and regulating all of the major systems in the body. These include the immune system, the cardiovascular system, central nervous system, and gastrointestinal system. A properly functioning endocannabinoid system relies on having enough natural cannabinoids coursing through the bloodstream to bind with the body’s cannabinoid receptors.

As humans age, however, the natural cannabinoids upon which everyone relies for good health materially deplete. When this occurs, the cannabinoid receptors have nothing with which to bind, causing imbalances in the body. These imbalances are a primary cause of the aches, pains, and illness people suffer as they age. Cannabinoid levels can be restored, however, by the proper consumption of phytocannabinoids, such as those found in CBD oil.

This series will address the specific CBD needs of athletes, the aging, alcohol and nicotine users, caregivers, those suffering from chronic illness, and others. It will address how CBD helps the body’s physiology, how to optimize CBD consumption, and how to use CBD to potentially achieve certain health, wellness, and performance results.

Chris Bunka, CEO of Lexaria Corp said, “We are very excited to have Dr. Reillo write these education manuals on Lexaria’s behalf. The CBD industry is in its infancy, and the benefits of CBD consumption are only just now being understood. We believe that as a producer of CBD products, it is our obligation to make sure that our customers understand how to use our products to achieve the maximum health and performance benefits possible. Michelle is one of the foremost authorities and leading researchers on CBD in the world and we’re certain her work will benefit each of Lexaria’s customers.”

We remind all consumers that ViPovaTM uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPovaTM has this ground-breaking technology for CBD/lipid infusion.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Commissions Cannabinoid Education Series

CLIENT FEATURE: Lexaria (LXX: CSE) Application in Progress to Produce 10,000kg of Med Marijuana Per Year

Posted by AGORACOM-JC at 11:35 AM on Wednesday, January 7th, 2015

(LXX: CSE, LXRP: OTCQB)

Regulated Marijuana Production

  • Burlington joint venture approximately 75,000 sq ft in total potential space
  • Applied to produce 10,000kg of Medical Marijuana per year
  • Planned production areas have 22 foot ceilings which will allow for the possibility of a 2nd mezzanine level in many areas, allowing for additional future expansion.
  • Closed 51% acquisition of Poviva Tea, LLC

Gupta: ‘I am doubling down’ on medical marijuana


Dr. Sanjay Gupta, CNN Cheif Medical Correspondent. We have no affiliation with this well known medical expert, but his latest “Doubling Down” on the medical marijuana sector is worthy of your attention. Reasons such as these convince us we are doing the right thing in entering this market.

Medical marijuana and ‘the entourage effect’

Today, most Americans and most Canadians support some form of medical use of marijuana, in poll after poll.

Likewise, the legal marijuana industry is and will be heavily regulated, and we support that. We’ve already proven our ability to be transparent with our stakeholders and our ability to work within all applicable government regulations. We promise to deliver that transparency and dedication to the legal marijuana industry where these traits are a vital component towards ultimate success.


The medical marijuana business just might be one of the most recession-proof industry sectors there are. There is no boom and bust cycle that is apparent. The average demographic age in North America continues to increase, with over 44 million people in the USA today at the age of 65 or over. Age-related illnesses will continue to grow, and some fraction of these people looking for an alternative to opiate-based painkillers have a real need for pain-relief choices.

12 Month Stock Chart


Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, Lexaria Corp., Medical Marijuana Stocks | Comments Off on CLIENT FEATURE: Lexaria (LXX: CSE) Application in Progress to Produce 10,000kg of Med Marijuana Per Year

« Older Entries
Newer Entries »